Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo

Curie: Healthcare in Focus
11/12/2024 5 min Temporada 1 Episodio 6
Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo

Listen "Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo"

Descargar episodio Ver en sitio original

Episode Synopsis

On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights! Like what you hear? Download Curie from the App store for personalized insights.

More episodes of the podcast Curie: Healthcare in Focus

The Preconception Revolution with Dr. Ann Shippy 04/11/2025
From Breakdown to Breakthrough - A Physician’s Reckoning with Burnout 28/10/2025
The Wellness Industrial Complex: What Influencers Reveal About Modern Medicine 21/10/2025
Autopilot Medicine: The Danger of Getting Too Good at AI 14/10/2025
Tylenol & Autism: What Clinicians Should Know (and Watch For) 07/10/2025
Replaceable You – Mary Roach on the Miracles We Can’t Copy 30/09/2025
The Great American Healthcare Heist with Chris Deacon 23/09/2025
From Bedside to Boardroom - Krista Bragg on Bridging Clinician and Executive Perspectives 16/09/2025
AI Scribes – The Hidden Cost of Progress 09/09/2025
Dr. Nasser Hanna - A Life in Medicine, Mentorship, and Advocacy 26/08/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA